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Abstract
In the last decade there have been multiple studies concerning the contribution of endothelial progenitor cells
(EPCs) to new vessel formation in different physiological and pathological settings. The process by which EPCs
contribute to new vessel formation in adults is termed postnatal vasculogenesis and occurs via four inter-related
steps. They must respond to chemoattractant signals and mobilize from the bone marrow to the peripheral blood;
home in on sites of new vessel formation; invade and migrate at the same sites; and differentiate into mature
endothelial cells (ECs) and/or regulate pre-existing ECs via paracrine or juxtacrine signals. During these four steps,
EPCs interact with different physiological compartments, namely bone marrow, peripheral blood, blood vessels and
homing tissues. The success of each step depends on the ability of EPCs to interact, adapt and respond to multiple
molecular cues. The present review summarizes the interactions between integrins expressed by EPCs and their
ligands: extracellular matrix components and cell surface proteins present at sites of postnatal vasculogenesis. The
data summarized here indicate that integrins represent a major molecular determinant of EPC function, with
different integrin subunits regulating different steps of EPC biology. Specifically, integrin a4b1 is a key regulator of
EPC retention and/or mobilization from the bone marrow, while integrins a5b1, a6b1, avb3 and avb5 are major
determinants of EPC homing, invasion, differentiation and paracrine factor production. b2 integrins are the major
regulators of EPC transendothelial migration. The relevance of integrins in EPC biology is also demonstrated by
many studies that use extracellular matrix-based scaffolds as a clinical tool to improve the vasculogenic functions
of EPCs. We propose that targeted and tissue-specific manipulation of EPC integrin-mediated interactions may be
crucial to further improve the usage of this cell population as a relevant clinical agent.
Review
Postnatal vasculogenesis and endothelial progenitor cells
The cardiovascular system is the first functional organ
system to develop in the vertebrate embryo and is
required for embryonic survival to regulate multiple
homeostatic functions in the developing embryo [1].
New blood vessel formation (neovascularization) is an
essential mechanism determining the formation, but
also the maintenance, of the cardiovascular system. It is
thought to depend mainly on two processes, angiogen-
esis and vasculogenesis.
Angiogenesis is the process by which new vessels are
formed by the activation, proliferation and migration of
endothelial cells (ECs). Vasculogenesis is defined as the
process by which new vessels are generated, by the
migration and differentiation of vascular endothelial
growth factor receptor 2 positive (VEGFR-2+) mesoder-
mal precursors, termed angioblasts and/or hemangio-
blasts, into ECs that coalesce to form a primary vascular
plexus during embryonic development [2].
The existence of an equivalent process during adult-
hood - postnatal vasculogenesis - has been intriguing
vascular and hematologic researchers since the early
20th century, when the first studies describing blood
vessel formation from peripheral blood (PB) and bone-
marrow (BM) mononuclear cells were published. These
studies suggested the existence of a population of cells
in the PB and/or BM capable of generating ECs when
cultured under specific conditions [3-5]. However, it
was only in 1997 that Asahara et al. [6] isolated and
characterized CD34+ or VEGFR-2+ cell populations for
the first time, derived from PB capable of differentiating
into ECs in vitro when plated on fibronectin (FN) and
exposed to angiogenic growth factor stimuli, namely
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ingly, using an in vivo animal model of hind limb
ischemia, these authors showed that CD34+ and
VEGFR-2+ cells were incorporated into newly formed
vessels and acquired the expression of EC antigens.
These cells where thus termed endothelial progenitor
cells (EPCs) [6]. In accordance, Shi Q et al [7]
reported the existence of ‘circulating bone marrow-
derived endothelial progenitor cells’ in the adult and
showed that these cells were derived from BM. Circu-
lating BM-derived EPCs were defined as a subset of
CD34+ hematopoietic stem cells with the ability to
differentiate into the endothelial lineage and express
endothelial marker such as von Willebrand Factor
(vWF) and incorporate acetylated Low Density Lipo-
protein (Ac-LDL). Most convincingly, these authors
showed that bone marrow-transplanted genetically
tagged cells contributed to the endothelialization of a
Dacron graft placed on the descending thoracic aorta
in dogs. Later, in 2000, Peichev et al. added to the
molecular definition of human EPCs, showing that
these express CD133+ (prominin), CD34+ and
VEGFR-2+, and are present in adult mobilized PB,
cord blood and also fetal livers. This pioneer study
proposed that CD133, together with other endothelial
markers, including VEGFR2 and CD34, could be used
to distinguish EPCs from mature ECs and also from
other tissue stem cells [8]. The proof of existence for
EPCs and the demonstration of their ability to differ-
entiate into mature ECs and incorporate blood vessels
was a key finding to support the existence of postnatal
vasculogenesis.
The biological significance of EPCs is supported by
accumulating evidence from the last decade showing
that this cell population contributes in a quantitative
manner to postnatal vasculogenesis in multiple condi-
tions These include physiological, such as neonatal tis-
sue growth [9,10], and pathological conditions, such as
peripheral vascular disease [11], myocardial and limb
ischemia [12,13], stroke [14], tissue regeneration [15-18],
retinopathy [19], artherosclerosis [20] and tumor growth
[21-24]. Given their significant biological contribution in
different types of vascular pathologies, EPCs and their
biology have been under intense investigation for the
last decade. Most studies have focused on the molecular
definition of EPCs, on the molecular mechanisms regu-
lating EPC function, the quantitative determination of
EPC contribution to physiological and/or pathological
postnatal vasculogenesis and, more recently, on the clin-
ical and therapeutic applications of this cell population.
In the next sections of this review we will update and
resume some of these aspects with a major focus on the
importance of integrin-mediated interactions (adhesion)
on EPC biology and function.
Molecular definition(s) of endothelial progenitor cells
A consensus as to the markers that define EPCs has not
been reached; different authors use various combinations
of surface and functional markers to isolate and study
EPCs in different contexts. In the context of this review,
EPCs will be defined as BM-, PB-, cord blood- or fetal
liver-derived nonendothelial cells that have stemness
properties and markers (CD133+, CD34+, c-Kit+/Sca-1
+); are capable of clonal expansion; and are able to differ-
entiate into adherent ECs, acquiring endothelial proper-
ties and markers (CD146+, CD31+, CD105+, vWF+,
tyrosine kinase with immunoglobulin-like and EGF-like
domains-2+, vascular endothelial cadherin+ and VEGFR-
2+) [25-27]. A more comprehensive definition of EPC
markers is beyond the scope of this review.
Endothelial progenitor cell biology and function during
postnatal vasculogenesis
Since EPCs were first described there have been numer-
ous studies concerning their biology and function. In
the last decade, it has been established that, in order to
exert their ‘vascular function’, EPCs have to accomplish
four distinct but interrelated steps. They must respond
to chemoattractant signals and mobilize from the BM to
the PB; home in on sites of vascular remodeling, repair
and angiogenesis; invade andm i g r a t ea tt h es a m es i t e s ;
and differentiate into mature ECs and/or regulate pre-
existing ECs via paracrine or juxtacrine signals [28].
Some of the major molecular regulators that deter-
mine these four steps have been identified (Figure 1). In
Figure 1 Molecular mechanism regulating the multiple steps of
endothelial progenitor cell biology during postnatal
vasculogenesis. Recruitment and incorporation of EPCs into angiogenic
sites requires a coordinated multistep process including mobilization,
chemoattraction, adhesion, endothelial transmigration, migration, tissue
invasion, in situ differentiation and paracrine and/or juxtacrine factor
production. The major molecular mechanisms that have been implicated
in the distinct steps of EPC biology are indicated. Figure adapted from
Fusenig N, Marmé D (eds): Tumor Angiogenesis: Basic Mechanisms and
Cancer Therapy. Springer; 2008. Chapter 17 with modifications [126].
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in the BM characterized by low oxygen tension [29] and
high levels of stromal cell-derived factor-1 (SDF-1), a
potent chemoattractant for EPCs that binds via the
receptor CXC chemokine receptor type 4 (CXCR4) [30].
EPCs are mobilized from the BM in response to periph-
eral tissue hypoxia and trauma, which cause the produc-
tion and release of EPC mobilizing factors such as
granulocyte-monocyte colony stimulating factor, granu-
locyte colony stimulating factor, VEGF, basic fibroblast
growth factor, placental growth factor, erythropoietin or
SDF-1 to a concentration greater than that in the BM
[28]. These factor act via the phosphoinositide 3-kinase/
protein kinase B (Akt) pathway to activate endothelial
nitric oxide synthase, leading to an increased production
of nitric oxide, which regulates the enzymatic activity of
matrix metalloproteinases (MMPs) [31,32]. In particular,
activated MMP-9 leads to the release of soluble kit
ligand from EPCs in the BM, allowing the cells to move
out to the peripheral circulation [33].
Once in circulation, EPCs home in on activated tis-
sues in response to chemokine gradients that are
formed in the tissue regions undergoing active remodel-
ing. The major chemokines and respective receptors
that regulate EPC activation and homing are SDF-1 and
CXCR4; IL-8 and CXCR2; growth regulated oncogene-a
and CXCR1; and C-C chemokine and chemokine (C-C
motif) receptors 2 and 5 [34-39]. Upon interaction with
tissue-specific chemokines, EPCs become activated and
initiate integrin-mediated adhesion to endothelial vascu-
lar cells and consequently transendothelial migration
into sites of vascular and tissue remodeling. The major
integrins and respective ligands that mediate these steps
of EPC function will be discussed in detail in the pre-
sent review.
Once circulating EPCs have crossed the endothelial
monolayer, they need to migrate through the blood ves-
sel basement membrane and through the interstitial
extracellular matrix (ECM) in order to arrive at the spe-
cific niches where they can exert their functions. EPC
invasion depends to a great extent on the activity of
extracellular proteases that breakdown and remodel
ECM components at the vessel basement membrane
and also in the interstitial space. The major extracellular
proteases involved in EPC invasion are members of the
MMP family (in particular MMP-9 [40]), members of
the cathepsin family (cathepsin L [41]) and also the ser-
ine protease urokinase-type plasminogen activator and
tissue-type plasminogen activator [42].
When the EPCs arrive at sites of vessel remodeling
they will contribute to new vessel formation and remo-
deling. The mechanisms that contribute to the func-
tional activity of EPCs are still under investigation.
However, functional activity of EPCs depends mainly on
two processes: differentiation into mature ECs and
direct incorporation into neovessels and/or production
of paracrine and/or juxtacrine signals that promote
interactions with pre-existing ECs and other cell types.
The differentiation of EPCs into ECs is a very complex
process that can be subdivided into three steps [43].
First, there is integrin-mediated adhesion to ECM com-
ponents. The direct interaction between integrin a5b1
and FN in particular have been shown to be essential in
the initial steps of EPC differentiation [44]. Second,
there is growth factor-induced proliferation and survival:
the VEGF family of growth factors and also the angio-
poietin-tyrosine kinase with immunoglobulin-like and
EGF-like domains 1 receptor pathway [45] have been
implicated in the regulation of EPC proliferation and
survival. Third, the maturation and acquisition of an
endothelial phenotype is an essential step in EPC biol-
ogy and depends mainly on the regulation of the tran-
scription factor HoxA, which is transcriptionally
regulated by histone deacetylases. Accordingly, HoxA9
has been shown to regulate the expression of the
endothelial genes for endothelial nitric oxide synthase,
VEGFR-2 and vascular endothelial cadherin [46]. Besides
differentiating into ECs, EPCs have been shown to pro-
duce multiple paracrine factors such as VEGF, SDF-1,
insulin-like growth factor 1, monocyte chemotactic pro-
tein 1 (MCP-1), macrophage inflammatory protein 1a
and platelet derived growth factor [47,48]. Altogether
these factors can act on different cell types leading to an
overall response that promotes angiogenesis and tissue
regeneration.
Integrin-extracellular matrix interactions in endothelial
progenitor cells biology
Throughout the main steps that regulate EPC function -
mobilization, homing, invasion and differentiation and/
or paracrine factor production - EPCs interact with dif-
ferent physiological compartments, namely BM, PB,
blood vessels and homing tissues. Therefore what deter-
mines the success of each step is the ability of EPCs to
interact, adapt and respond to multiple molecular cues
present in each compartment. Considering this,
although some of the molecular pathways regulating the
multiple steps of EPC biology have been addressed (Fig-
ure 1), in the present review we will summarize the
known contributions of structural and/or morphogenic
signals to EPC biology, in particular the interaction
between integrins expressed by EPCs and their ligands,
ECM components and cell surface proteins present at
sites of vascular repair/remodeling. We propose that tar-
geted manipulation of integrin-ECM interactions in
EPCs and at sites of vascular remodeling may contribute
to the improvement of EPC-mediated vascular repair
and function.
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all tissues and organs that provides not only an essential
physical scaffold for the cellular constituents but also
initiates crucial biochemical and biomechanical cues
that determine cell differentiation, proliferation, survival,
polarity and migration. It thus plays an essential role in
tissue morphogenesis, differentiation and homeostasis
[49]. The ECM is mainly composed of two main classes
of macromolecules: proteoglycans and fibrous proteins
[50,51]. The main fibrous ECM proteins are collagens,
elastins, FNs and laminins. Proteoglycans (namely perle-
can) fill the majority of the extracellular interstitial
space within the tissue in the form of a hydrated gelatin.
The direct effect of ECM components in cell behavior
derives mainly from two ECM properties: their ability to
bind directly to their cellular receptors, integrins and
discoidin domain tyrosine kinase receptors - which in
turn are signal transduction receptors; and their ability
to bind and present growth factors as organized solid-
phase [49]. As mentioned earlier, in the present review
we will focus mainly on the contribution of ECM-integ-
rin interactions on EPC biology.
Integrins are a family of non-covalently associated het-
erodimeric transmembrane glycoprotein adhesion pro-
teins which mediate cell-ECM and cell-cell interactions.
Integrins are responsible for cellular tissue architecture
and also function as signal transducers regulating survi-
val, proliferation, differentiation and migratory signaling
pathways. Each integrin is composed of two subunits:
one a- (around 800 amino acids) and one b-subunit
(approximately 1,000 amino acids). In higher vertebrates,
eighteen a- and eight b-subunits combine to form more
than 24 different integrin heterodimers. Heterodimer
composition confers ligand specificity, with most integ-
rins recognizing several ECM proteins that in turn bind
to more than one integrin [52].
Integrin expression in endothelial progenitor cells
In agreement with multiple studies concerning the
expression of integrin subunits on EPCs, we can define
an integrin expression profile on EPCs. Accordingly,
EPCs express integrin subunits a1, a2, a3, a4, a5, a6,
a9, av, b1, b2, b3, b5a n db7 [43,44,53-61]. Despite the
expression of so many different integrin subunits by
EPCs, it is apparent that some of these integrins can in
fact be activated and/or upregulated at specific steps of
EPC biology as reflex to the multiple molecular cues
( t i s s u es p e c i f i cE C Ma n ds o l u b l ef a c t o r s )t h a tm a yb e
present. This suggests that the integrin expression pro-
file of EPCs is in fact a dynamic aspect of EPC biology
reflecting the adaptation of these cells to different con-
ditions. In the next sections we will summarize the
reported functions of each integrin subunit in EPC biol-
ogy (Table 1).
Integrin-mediated endothelial progenitor cell mobilization
from the bone marrow - integrin subunits a4 and b3
The main integrins regulating the mobilization of EPCs
from the BM microenvironment are the a4 integrins.
These have been proven essential for embryogenesis,
hematopoiesis, lymphocyte homing and the recruitment
of leukocytes to sites of inflammation [62]. The a4
integrins, a4b1 and a4b7 are most prominent on mono-
nuclear leukocytes, but can also be expressed in neutro-
phils, hematopoietic stem cells and EPCs [63,64]. a4b1
mediates cell adhesion to vascular cell adhesion mole-
cule-1 (VCAM-1) and to an alternatively spliced form of
the extracellular matrix protein, FN [65]. a4b7 is impor-
tant in lymphocyte homing to mucosal tissue by adher-
ing to the gut homing receptor mucosa addressing cell
adhesion molecule and it also binds to VCAM-1 and FN
[66-68]. Concerning their role on EPC mobilization, it
has been shown that in vitro usage of anti-a4i n t e g r i n
Table 1 Overview of the major integrin sub-units and respective ligands involved in endothelial progenitor cell
biology.
Integrin Main ligand Role on EPC biology References
a4b1 FN; VCAM-1 Bone marrow retention and/or mobilization;
homing and/or adhesion to angiogenic sites
[63,72]
a5b1 FN Homing and/or adhesion to angiogenic sites;
invasion and migration;
differentiation and paracrine/juxtacrine interaction
[44,69,83,96-98]
a6b1 Laminin Homing and/or adhesion to angiogenic sites;
invasion
[56,87]
b2 integrins Fibrin(ogen); ICAM-1/2 Homing and/or adhesion to angiogenic sites;
transendothelial migration
[72-74,90,91]
avb3 RGD Homing and/or adhesion to angiogenic sites;
bone marrow retention and/or mobilization (b3 subunit)
[69,88,98]
avb5 RGD Homing/adhesion to angiogenic sites;
differentiation and paracrine and/or juxtacrine interaction (b5 subunit)
[88,89,98,99]
EPC: endothelial progenitor cell; FN: fibronectin; ICAM-1/2: intercellular adhesion molecule 1/2; RGD: arginine-glycine-aspartate motif; VCAM-1: vascular cell
adhesion molecule 1.
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tions between BM-derived EPCs and immobilized
VCAM-1, FN (to a smaller extent) or BM stromal cells.
Moreover, systemic administration of anti-a4i n t e g r i n
antibody or conditional knockout of a4i n t e g r i ni nt h e
BM significantly increases the number of circulating
EPCs, suggesting that this integrin is essential for retain-
ing EPCs in the BM [63]. Interestingly, after ischemic
injury, integrin a4 blockade results in an increase in the
number of BM-derived EPCs present in the neovascula-
ture at the ischemic tissue and augments the recovery of
blood flow and tissue preservation. Altogether, these
authors establish that a4 integrin plays an important
role in BM-derived EPC mobilization and that func-
tional disruption of a4 integrin-mediated EPC retention
in the BM causes a shift toward a distribution of EPCs
into circulation that favors neovascularization.
Another integrin subunit that has been implicated in
the retention of EPCs in the BM is the integrin b3.
These integrins have essential roles in angiogenesis,
hemostasis and in bone remodeling, being essentially
expressed on ECs, platelets, osteoclasts and hematopoie-
tic cells [52]. Concerning EPC mobilization, a recent
paper by Watson et al. shows that b3 integrins are
necessary for the retention of EPCs in the BM, since
wild-type mice receiving b3 integrin-null BM show
increased EPCs mobilization to the PB and consequent
increased tumor vascularization. However, a high pro-
portion of the vessels are nonfunctional and therefore
do not enhance tumor growth, further suggesting that
integrin b3 might affect other EPC properties besides
BM mobilization [69].
Integrin-mediated endothelial progenitor cells homing to
sites of vascular remodeling, repair and angiogenesis
After being mobilized from the BM into the PB, EPCs
become a small percentage of the circulating cells along
with other hematopoietic populations. Considering this,
EPCs must be specifically responsive to signals present
at injury and remodeling ECs as opposed to signals pre-
sent in normal and quiescent ECs. Recognizing such sig-
nals enables EPCs to home to sites of vessel injury and
remodeling, where they become activated by local che-
mokines and cytokines, adhere to activated ECs or ECM
components and incorporate and differentiate into
newly formed vessels, or act via paracrine and/or juxta-
crine interactions on pre-existing ECs. Direct evidence
of EPC homing and incorporation into neovasculature
has been addressed by Vajkoczy et al. using intravital
fluorescence videomicroscopy and murine embryonic
EPCs in a tumor model. According to this study
embryonic EPC homing to tumor vasculature occurs
mainly by sticking (active adhesion to tumor vasculature
without affecting blood flow) and not by plugging tumor
blood vessels (size restrictions or dead-end vascular
sprouts), contrary to what happens in normal vascula-
ture [70]. This data suggests that EPC homing is an
active process involving direct interaction between
molecular targets expressed on homing tissues and
adhesion molecules, namely integrins, expressed by
EPCs.
b2 integrins in endothelial progenitor cell homing
There are numerous studies reporting the role of integ-
rins during EPC homing to sites of neoangiogenesis.
One of the major integrin subunits regulating EPC hom-
ing to active angiogenic sites is the b2 integrin. b2 integ-
rins are described as leukocyte specific receptors,
recognizing essentially multiple members of the intercel-
lular adhesion molecule (ICAM) family and polysacchar-
ides [71]. These integrins are essential for the regulation
of hematopoiesis, leukocyte recruitment and inflamma-
tory cells [52]. Despite the specificity of integrin b2
expression in leukocytes, many studies have described
its expression in EPCs [61,71-73]. In vitro adhesion stu-
dies show that b2 integrins mediate the adhesion of
adult PB-derived EPCs to pre-activated EC monolayers
a n da l s ot oI C A M - 1a n df i b r i n o g e n .A d d i t i o n a l l y ,t h e
same study revealed that b2 integrins and its activation
status play an essential role not only in the homing of
BM-derived EPCs to ischemic tissues but also in the
neovascularization capacity of these cells in vivo. Further
supporting the role of integrin b2 and its activation on
EPC homing is the fact that the addition of pharmacolo-
gical activators of exchange protein directly activated by
cyclic AMP (a nucleotide exchange protein for ras-
related protein 1 that activates integrin conformation) to
EPCs increases b2-integrin-dependent adhesion to
ICAM-1, migration on fibrinogen and, consequently, the
homing and neovascularization-promoting capacity of
intravenously injected EPCs [74].
b1 integrins in endothelial progenitor cell homing
In spite of the described role of b2 integrins on EPC
homing, multiple studies have shown that its inhibition
leads only to a partial inhibition of EPC homing, sug-
gesting that other integrins may also regulate this essen-
tial step of EPC biology. One of the major integrin
families regulating EPC homing to angiogenic sites is
the b1 integrins.
In particular integrin a4b1 is highly expressed in EPCs
and has been shown to mediate in vitro adhesion of
EPCs to pre-activated EC monolayers, specifically to
VCAM-1 and cellular FN [63]. Furthermore, in in vivo
models of breast cancer, inhibition of a4b1 integrin sig-
nificantly blocks homing of BM-derived EPCs cells to
tumor neovessels expressing its ligands FN and VCAM-
1 [72]. Interestingly, as mentioned before, a4b1b l o c k -
ade can in fact mobilize EPCs from the BM and increase
their number in the PB, thus indicating that targeting
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mobilization but decreasing their homing to angiogenic
sites.
Besides recognizing molecular homing signals expressed
by activated ECs, EPCs can recognize and adhere directly
to exposed ECM components. a5b1i n t e g r i ni sa nF N
receptor, which binds to the arginine-glycine-aspartic acid
(RGD) motif region of FN [75]. Studies using various cell
culture systems have suggested that a5b1i si n v o l v e di n
many cellular processes including cell proliferation, onco-
genic transformation, assembly of FN-rich extracellular
matrices, cell migration, regulation of gene expression,
wound healing, T-cell activation, angiogenesis and embry-
ogenesis - where it regulates mesodermal formation and
function [76-80]. Integrin a5b1 is also highly expressed in
EPCs and is directly involved in the homing of EPCs to
denuded vessels, where its ligand FN rapidly accumulates
[81]. Accordingly, treatment of EPCs with statins increases
the expression levels of integrin a5b1, consequently
increasing EPC homing to vascular injury sites and thus
promoting re- endothelialization of these sites [59].
In agreement with the above, a recent report describes
the direct interaction between EPCs integrin a5b1a n d
FN under laminar shear stress, suggesting that EPC
adhesion to exposed FN on blood vessels can occur
under physiological levels of shear stress [82]. The role
of a5b1 in EPC homing is further supported in models
of lung vascular injury, where these integrins, together
with a4b1 integrin, mediate the homing and adhesion of
EPCs to damaged pulmonary capillaries, further contri-
buting to the repair of the endothelial barrier and pre-
venting lung vascular damage [83].
Another b1 integrin associated with EPC homing to
sites of neovascularization is the integrin a6b1. a6b1
integrin is a laminin-binding integrin that is essential for
skin homeostasis [84], regulates endothelial tube forma-
tion [85]and also contributes to hematopoietic stem cell
homing to the BM [86]. Concerning EPCs, a recent
work by Bouvard et al. has shown that integrin a6b1i s
directly regulated by VEGF and basic fibroblast growth
factor and is necessary for EPC homing to ischemic ske-
letal muscle in vivo and to EPC adhesion to basement
membrane components in vitro. According to these
authors, vessel obstruction leads to reduced oxygen sup-
ply and consequent death and detachment of the ECs
lining the walls, exposing the underlying basement
membrane components (namely laminins). Exposed
laminin may then function as as p e c i f i ch o m i n gs i g n a l
for EPCs expressing integrin a6b1, thus directing EPCs
to sites of vascular injury where these cells can restore
vascular integrity [56,87].
av integrin in endothelial progenitor cell homing
Integrins av( n a m e l yavb3- and avb5-integrins) also
play a role in EPC homing to sites of vascular repair. av
integrins are expressed on almost all the cells originat-
ing from the mesenchyme and mediate many biologic
events, such as migration of vascular smooth muscle
cells (SMCs), adhesion of osteoclasts to the bone matrix
and angiogenesis. av integrins are known to bind differ-
ent ligands, including vitronectin, FN, osteopontin, fibri-
nogen and vWF, by interacting with the RGD motif
[52]. Interestingly, EPC adhesion to denuded vessels
appears to be also mediated by avb3- and avb5-integ-
rins, since inhibition of avb3- and avb5-integrins with
cyclic RGD peptides blocks EPC-mediated re-endothe-
lialization of denuded arteries [88]. In agreement, integ-
rin avb5 has been described as essential to the adhesion
of EPCs to differentiated endothelial cells [89].
Integrin-mediated endothelial progenitor cells
transendothelial migration
Once EPCs adhere at specific homing sites they need to
migrate through the endothelial monolayer and invade
the underlying tissue. Concerning EPCs, very little is
known in relation to integrins mediating transendothe-
lial migration. In human adult PB-derived EPCs, trans-
endothelial migration appears to be mediated mainly by
b2 integrins and depends on MCP-1 and VEGF [90].
This is further supported by a study showing that
increased expression of ICAM-1 in ECs, via Akt activa-
tion, increases EPC homing and transendothelial migra-
tion in in vitro assays [91].
Integrin-mediated endothelial progenitor cell invasion
and migration
As EPCs cross the endothelial monolayer, they need to
migrate through the blood vessel basement membrane
and through the interstitial ECM in order to arrive at
the specific niches where they can exert their functions.
These processes require multiple cell-ECM interactions
a n dd e p e n dm a i n l yo nt h ei n tegrin-ECM interactions
and on extracellular proteases-ECM interactions. The
essential role of the ECM as a provider of biochemical
and biophysical cues that regulate EPCs cellular beha-
vior is addressed in a recent report by Hanjaya-Putra et
al., where the authors show that the ECM stiffness mod-
ulates EPC invasion. In detail, EPCs can sense matrix
stiffness through signaling cascades downstream of
integrin ligation leading to the activation of the Rho
guanosine triphosphate hydrolase, cell division control
protein 42 homolog. Accordingly, if the matrix stiffness
is high, EPCs upregulate the production of extracellular
proteases that allow both matrix degradation and EPC
migration [92]. This study revealed that both integrins
and extracellular proteases are essential to modulate
EPC invasion and migration along the ECM. The contri-
bution of integrins to EPC invasion and migration is
further supported by Wijelath et al. These authors show
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towards a VEGF gradient, in vitro [44]. In another
study, integrin a6b1 is described as an essential integrin
regulating EPC adhesion and migration towards VEGF,
in a phosphatidylinositol 3-kinase/Akt pathway depen-
dent way. Furthermore, the same authors show that
a6b1 integrin mediates EPC invasion and consequent
tube formation in vitro and in vivo, being essential for
EPC-mediated collateral vessel formation in ischemic
hind limb mouse models [56,87].
Role of integrin-endothelial progenitor cell interactions
on endothelial progenitor cell differentiation
The functional activity of EPCs depends mainly on two
interdependent processes: differentiation into mature
ECs and direct incorporation into neovessels and/or
production of paracrine and/or juxtacrine signals that
promote interactions with pre-existing ECs and other
cell types. Concerning EPC differentiation into EC, a
s t u d yb yo u rl a b o r a t o r yh a ss h e ds o m el i g h to n t ot h e
molecular pathways that modulate the different steps of
EPC differentiation. We defined a global gene-expres-
sion profile of cord blood-EPC (CD133+, CD34+ and
kinase insert domain receptor +) during the process of
endothelial differentiation in vitro. The gene profile data
of EPC differentiation reveals a strict temporal regula-
tion of endothelial differentiation, which can be divided
into three sequential and distinct stages: integrin-
mediated adhesion to specific ECM components; growth
factor-induced proliferation and survival; and matura-
tion and functional acquisition of EC properties [43].
EPC adhesion to the ECM is an essential step during
differentiation, allowing cells to attach onto a substrate
and to acquire proliferative and survival signals from the
underlying matrix. Moreover, direct interaction between
integrins and ECM can regulate EPC paracrine factor
production. Interestingly, the integrin expression profile
in EPCs is variable throughout endothelial differentia-
tion, further suggesting that integrin-ECM interactions
can mediate different aspects of the endothelial differen-
tiation process. In detail, integrin a9i so n l ye x p r e s s e d
in undifferentiated EPCs (day 0 of differentiation), while
b5a n db7 are only expressed in differentiating EPCs
(day 13). On the other hand, integrin subunits a4, a5
and av are expressed throughout EPC differentiation.
All the non-variable integrin subunits are FN-binding
integrins, further pointing out that direct interaction of
EPCs with FN is essential during endothelial differentia-
tion. In fact, FN has been shown to be essential for vas-
culogenesis during embryonic development, as well as
its receptor integrin a5b1. Accordingly, genes for FN
and integrin subunit a5 are among the 12 genes consid-
ered critical for vasculogenesis since knockout mice for
these genes are embryonic lethal with major vascular
defects [93-95]. Concerning EPCs, early work by Asa-
hara et al. revealed for the first time that these cells
show higher adhesion and endothelial differentiation
when plated on FN compared to collagen [6]. More
recently, the role of the FN-integrin a5b1 interaction in
EPC differentiation has been addressed. FN is described
as a major regulator of EPC differentiation since it pro-
motes VEGF-induced differentiation of EPCs into ECs
via specific binding to integrin a5b [44]. Although the
precise mechanism by which FN and VEGF synergy reg-
ulates EPC differentiation is not clear, it is possible that
the formation of FN/VEGF complexes by direct interac-
tions of VEGF with FN heparin-II domain [96] leads
firstly to the physical association between VEGFR-2 and
a5b1 [97] and consequently to the activation of down-
stream pathways that may potentiate EPC endothelial
differentiation.
The contribution of integrin-ECM interactions in EPC
differentiation is further demonstrated in a recent study
showing that vascular endothelial growth inhibitor, a
known anti-angiogenic cytokine, impairs EPC adhesion
and differentiation on both FN and vitronectin by down-
regulating the expression of integrin subunits a5a n d
av, further suggesting the importance of both integrins
during EPC differentiation [98]. Besides differentiating
into ECs, EPCs can produce multiple paracrine factors
that in turn can act on other cell types influencing mul-
tiple cellular processes. Interestingly, there is some data
suggesting that integrin-ECM interactions can influence
EPC paracrine factor production. For instance, integrin
b5 regulates EPCs paracrine factor production. Overex-
pression of integrin b5 in EPCs results in integrin avb5
phosphorylation, activation of proto-oncogene tyrosine-
protein kinase and activation of transcription factor
S T A T 3 ,w h i c hi nt u r ni n d u c ee x p r e s s i o no ft h ep r o -
angiogenic factors IL-8 and MCP-1 [99].
Recent investigation by Barsotti et al. shows that EPCs
plated on different matrices produce different amounts of
paracrine factors. For instance, when plated on fibrin,
EPCs expressed increased levels of multiple cytokines,
namely IL-16, platelet derived growth factor-BB, SDF-1,
hepatocyte growth factor (HGF), Interferon gamma-
induced protein 10 (IP-10) and monokine induced by
gamma interferon (MIG). This furthers suggests that the
paracrine factor production by EPCs is also regulated by
the integrin-ECM interactions [100]. Additionally, recent
data collected from our group also suggests that EPCs
grown on different ECM components produce different
levels of paracrine factors. We observed that EPCs grown
or gelatin, FN or on fibrin proteolytic fragment E (FbnE)
express different levels of multiple paracrine factors.
They showed higher expression of VEGF-A, transforming
growth factor b1, SDF-1, IL-8 and macrophage inflam-
matory protein-1a, however the precise mechanism
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and FbnE was not established [54].
Endothelial progenitor cells as therapeutic agents - how
to improve endothelial progenitor cell function in vivo:
extracellular matrix scaffolds
Since EPCs where first isolated, many in vitro and in
vivo preclinical studies have created great expectation
for their wide use in clinical practice. In fact, to date, a
dozen of complete interventional clinical trials concern-
ing the application of PB or BM-derived EPCs in cardio-
vascular diseases have been published (Table 2) while
many others are ongoing [111]. Despite the success of
the application of EPCs as therapeutic agents in cardio-
vascular disease, there are some limitations to the inter-
pretation of these clinical trials - namely the lack of
Table 2 Published interventional clinical trials using endothelial progenitor cells.
Disease Patient
numbers
Intervention Description Results Reference
Chronic
ischemic
heart
disease
121 Transcoronary transplantation
of bone marrow-derived
progenitor cells
Intracoronary infusion in patients
with chronic ischemic heart disease
Reduced serum levels of heart failure
markers;
reduced mortality
[101]
Idiopathic
pulmonary
arterial
hypertension
33 Transplantation of
autologous EPCs
(differentiated from
peripheral blood
mononuclear cells)
Test safety, feasibility, and initial
clinical outcome of intravenous
infusion of autologous EPCs in
patients with idiopathic pulmonary
arterial hypertension
Feasible and safe infusion of
autologous EPCs is beneficial to
exercise capacity and pulmonary
hemodynamics in patients with
idiopathic pulmonary arterial
hypertension
[102]
Chronic
ischemic
heart
disease
75 Intracoronary infusion of
peripheral blood-EPCs and
bone marrow-derived
progenitor cells
Effect of intracoronary EPC infusion
on the left ventricular contractile
function
Feasible and safe transplantation of
bone marrow-derived progenitor cells
is associated with moderate but
significant improvement in the left
ventricular ejection fraction after three
months
[103]
Acute
myocardial
infarction
26 Intracoronary injection of
EPCs (differentiated from
peripheral blood
mononuclear cells)
Effect of intracoronary EPC infusion
on coronary vasomotion and left
ventricular function in patients after
recanalization of chronic coronary
total occlusion
Increased left ventricular ejection
fraction, coronary flow reserve;
reduction in infarct size
[104]
Acute
myocardial
infarction
11 Transcoronary transplantation
of bone marrow-derived
EPCs and mesenchymal stem
cells
Effect of transcoronary
transplantation of EPCs and
mesenchymal stem cells on
myocardial contractility and tissue
regeneration
Reduction in infarct size [105]
Acute
myocardial
infarction
59 Intracoronary infusion of
peripheral blood EPCs and
bone marrow-derived
progenitor cells
Effect of intracoronary EPC infusion
on left ventricular function, infarct
size and reactive hypertrophy
Increased left ventricular ejection
fraction, no reactive hypertrophy;
Reduction in infarct size
[106]
Critical limb
ischemia
28 Intramuscular injections of
peripheral blood granulocyte
colony stimulating factor
mobilized CD34+ CD133+
EPCs
Effect of intramuscular infusion on
and limb salvage rate for amputation
at 12 months
Implantation of EPCs in critical limb
ischemia is a safe alternative, improves
tissue perfusion, and obtains high
amputation-free rates
[107]
Acute
myocardial
infarction
366 EPC capture stent Safety and efficacy of EPC capture
stents in the acute myocardial
infarction settings
EPC stent is safe;
At two-year follow-up, the EPC group
showed favorable target vessel
revascularizations rate and stent
thrombosis remained a low-event
occurrence
[108]
ST elevation
acute
myocardial
infarction
100 EPC capture stent Safety and efficacy of EPC capture
stents in the ST elevation acute
myocardial infarction settings
The study does not support the use of
EPC capture stents with short duration
dual antiplatelet therapy in patients
with ST elevation acute myocardial
infarction
[109]
Refractory
angina
167 Intramyocardial injections of
autologous CD34+ cells
Effect of intramyocardial injections of
autologous CD34+ cells on refractory
angina patient
Intramyocardial injections of
autologous CD34+ cells improves
angina frequency and exercise
tolerance
[110]
EPC: endothelial progenitor cell.
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limitations are the use of distinct EPC populations,
routes of delivery used and timing of cell delivery, all
variables rendering cross-sectional comparison difficult
[111]. Concerning the routes of delivery, studies have
shown that the therapeutic capabilities of EPCs upon in
vivo systemic transplantation were insignificant, because
of their poor bio-distribution and low cell survival
[112,113]. To avoid these drawbacks, several studies
have attempted to inoculate EPCs directly at sites of
vascular repair and healing, including infracted areas of
the heart. Compared to systemic injection, this approach
led to significantly greater, but still marginal, numbers
of injected cells that survive in the infarct area and
eventually contribute to tissue regeneration [114]. To
overcome these limitations of conventional transplanta-
tion methods, there has been intense development of
scaffolds that promote in situ cell retention and avoid
non-specific cell homing. Considering the essential role
of integrin-ECM interactions in EPC biology there has
been a major effort to develop scaffolds constituted by
biologically or artificially derived ECM that provide
EPCs with ECM survival and proliferative and differen-
tiating signals, rendering EPC in vivo application more
efficient.
Biological scaffolds are composed of naturally occur-
ring polymers present in the ECM, namely proteins and
polysaccharides. The main proteins used for scaffold
composition are collagens, fibrin and gelatin. Collagen
matrices have been shown to support EPC differentia-
tion and vessel formation. According to a study by Crit-
ser et al., EPCs vascularize collagen-based matrices in
vivo although increasing collagen concentration signifi-
cantly decreased EPC-derived vessels density but signifi-
cantly increased vessel lumen sizes, suggesting that the
physical properties of collagen matrices influence EPC
vasculogenesis in vivo [115]. A more recent study
described the differentiation of progenitor cells into ECs
in a collagen matrix. This study showed that collagen
protects progenitor cells from apoptosis and increases
adhesion and invasion in an extracellular signal-regu-
lated kinase pathway-dependent way [116].
Fibrin is also involved in the regulation of EPC biol-
ogy. According to a recent study by Barsotti et al., when
plated on fibrin, EPCs can adhere and differentiate into
ECs to levels comparable to those obtained on FN, and
they also show enhanced cell viability and cytokine pro-
duction [100]. In another study, EPC exhibited biological
activity after in vivo subcutaneous implantation in a
fibrin matrix. Once in the fibrin matrix, EPCs migrate,
differentiate into ECs and integrate into newly formed
blood vessels [117]. Recent data from our laboratory
further suggests that FbnE plays an essential role in EPC
biology. We showed that FbnE potentiates the
vasculogenic properties of EPCs and also promotes
paracrine factor production. Moreover we observed that
administration of a FbnE-enriched scaffold together with
EPCs into mouse cutaneous wounds increases wound
vascularization and consequent healing [54].
Artificial matrices include a group of scaffolds that
mimic the ECM. These scaffolds combine biodegradable
and biocompatible scaffolds with small synthetic pep-
tides that mimic the integrin-binding sites of ECM
molecules. Examples are synthetic mimics of FN (RGD
and PHSRN) [118], laminin (Tyr-Ile-Gly-Ser-Arg motif
and Ile-Lys-Val-Ala-Val motif) [119], or collagens (type
I, Asp-Gly-Glu-Ala motif; type IV, Thr-Ala-Gly-Ser-Cys-
Leu-Arg-Lis-Phe-Ser-Thr-Met motif) [120,121]. The FN-
mimics RGD and PHSRN have both been implicated in
the differentiation of cells toward the endothelial lineage
[122]. A recent work by Alobaid et a.l showed an
enhanced attachment and increased endothelial out-
growth when EPCs were cultured on RGD-coated well
plates [123], while Ferreira et al. reported a 20-fold
increase in EC differentiation from embryonic stem cells
when these cells were encapsulated in a dextran-based
hydrogel containing the RGD peptide [118].
The use of scaffolds mimicking the ECM in physiolo-
gical processes was addressed by different investigators.
Blindt and colleagues investigated this concept by incor-
porating integrin-binding cyclic RGD (cRGD) peptide
with avb3-integrin-binding capacities into a newly
designed polymer stent-coating. This stent was analyzed
in in vitro and in vivo porcine models for its potential
to recruit and bind EPCs and limit coronary neointimal
formation. In vitro, the cRGD peptide stimulated the
outgrowth, shear-resistant recruitment and migration of
EPCs. In vivo, 12 weeks after implantation, both mean
neointimal area and mean percent area stenosis were
significantly reduced in cRGD peptide-loaded polymer
stents by accelerated stent endothelialization compared
with the control stents [124]. In another study, Kim et
al. described that targeted delivery of EPCs using an
RGD-g-poly-L-lactic acid scaffold enhances dermal
wound closure and vascularization in mouse models of
wound healing. EPCs grown on RGD-g-poly-L-lactic
acid scaffolds show increased proliferation, endothelial
differentiation and consequent incorporation on wound
vessels [125]. Together, these different approaches sug-
gest targeted manipulation of ECM and/or integrin
(adhesion) at vascular repair and formation sites may
improve EPC function and thereby improve the neovas-
cularization processes.
Conclusions
There has been great interest in manipulating EPCs for
neovascularization purposes, namely in the context of
tissue regeneration and vascular repair. As is certainly
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Page 9 of 13clear from the abundant body of literature cited in this
review, integrins play a crucial role in modulating sev-
eral aspects of EPC biology and function (Figure 2).
Therefore, although there has been some success in
using EPCs as therapeutic agents (as shown by recent
clinical trials), we suggest that targeted and tissue-speci-
fic manipulation of EPC-integrin interactions may be
crucial to further improve the usage of this cell popula-
tion as a relevant clinical agent.
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